Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience

Neoadjuvant Imatinib for Borderline Resectable GIST

(2017) M. Zach Koontz et al.   Journal of the National Comprehensive Cancer Network

Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib

(2012) R. Tielen et al.   EJSO

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

(2012) Heikki Joensuu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Gastrointestinal Stromal Tumors

(2012) Piotr Rutkowski et al.   Molecular Diagnosis & Therapy

The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones

(2011) Alessandro Gronchi et al.   ANNALS OF SURGICAL ONCOLOGY

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

(2011) Dian Wang et al.   ANNALS OF SURGICAL ONCOLOGY

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

(2011) Aurore Blesius et al.   BMC CANCER

Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors

(2011) Burton L. Eisenberg et al.   INTERNATIONAL JOURNAL OF CANCER

Surgical options for localized and advanced gastrointestinal stromal tumors

(2011) Timothy L. Frankel et al.   JOURNAL OF SURGICAL ONCOLOGY

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

(2011) Heikki Joensuu et al.   LANCET ONCOLOGY

Role of Surgery Combined with Kinase Inhibition in the Management of Gastrointestinal Stromal Tumor (GIST)

(2010) Peter Hohenberger et al.   ANNALS OF SURGICAL ONCOLOGY

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial

(2009) Axel Le Cesne et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis

(2008) John C. McAuliffe et al.   ANNALS OF SURGICAL ONCOLOGY

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)

(2008) M. Fiore et al.   EJSO

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

(2008) Burton L. Eisenberg et al.   JOURNAL OF SURGICAL ONCOLOGY